New Risk • May 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Ankündigung • May 05
Iofina plc, Annual General Meeting, Jun 09, 2026 Iofina plc, Annual General Meeting, Jun 09, 2026. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdom Reported Earnings • May 05
Full year 2025 earnings released: EPS: US$0.041 (vs US$0.015 in FY 2024) Full year 2025 results: EPS: US$0.041 (up from US$0.015 in FY 2024). Revenue: US$66.5m (up 22% from FY 2024). Net income: US$7.87m (up 170% from FY 2024). Profit margin: 12% (up from 5.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. New Risk • May 02
New major risk - Revenue and earnings growth Earnings have declined by 2.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.5% per year over the past 5 years. Minor Risk Large one-off items impacting financial results. Ankündigung • Apr 16
Iofina plc Provides Production Guidance for the First Half of Fiscal Year 2026 Iofina plc provided production guidance for the first half of fiscal year 2026. For the period, The Company now expects to exceed the previous H1 2026 production guidance of 325MT-355MT. Based on the current trends, the Company is now anticipating H1 2026 production to be closer to 385MT. New Risk • Apr 06
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (UK£49.3m market cap, or US$65.1m). Ankündigung • Jan 13
Iofina plc Provides Earnings Guidance for 2025 and Production Guidance for the First Half of 2026 Iofina plc provided earnings guidance for 2025 and production guidance for the first half of 2026. For the 2025, the company's revenue are projected to surpass $65 million.
For the first half of 2026, the company expects to produce between 325 MT-355 MT of crystalline iodine in H1 2026 (H1 2025: 305.5MT). Ankündigung • Dec 14
Iofina plc Announces the Proposed Appointment of Tim Hughes as a Non-Executive Director, Effective 1 January 2026 Iofina plc announced the proposed appointment of Tim Hughes as a Non-Executive Director, to take effect from 1 January 2026. Tim has significant experience in general management in the specialty chemical industry as well as corporate and sustainability matters. Tim was a member of the Executive Committee of Synthomer plc for 11 years until 2023 as divisional director for the industrial specialties global business, which included the company's specialty iodine business, before then becoming President of Corporate Development, where he was responsible for investor relations, external affairs and the development of the company's sustainability strategy. Prior to Synthomer, Tim led the Urethane Technologies joint venture business for Chemtura Corporation and spent 14 years in business leadership and marketing roles at Courtaulds plc. Tim is based in the UK and holds a BSc in Chemistry from the University of Manchester and an MBA from Cranfield University. Concurrent with his appointment, Tim will also be appointed as a member of Iofina's Audit and Remuneration Committees. Timothy John Hughes, age 61, is currently or has been a Director of the following companies within the past five years: Current Directorships at Catalyst Science Discovery Centre and Museum Trust Limited, Synthomer (UK) Limited and Chemical Industries Association Limited and Previous Directorships at Synthomer (UK) Limited. Price Target Changed • Dec 08
Price target increased by 20% to UK£0.45 Up from UK£0.38, the current price target is provided by 1 analyst. New target price is 88% above last closing price of UK£0.24. Stock is up 26% over the past year. The company posted earnings per share of US$0.015 last year. Ankündigung • Oct 17
Iofina plc Provides Production Guidance for the Second Half of 2025 Iofina plc provided production guidance for the second half of 2025. For the period, the company expects production is on track to be within the production range of 400 MT - 440 MT. New Risk • Sep 23
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (UK£44.6m market cap, or US$60.3m). Reported Earnings • Sep 23
First half 2025 earnings released: EPS: US$0.013 (vs US$0.003 in 1H 2024) First half 2025 results: EPS: US$0.013 (up from US$0.003 in 1H 2024). Revenue: US$29.2m (up 12% from 1H 2024). Net income: US$2.51m (up 313% from 1H 2024). Profit margin: 8.6% (up from 2.3% in 1H 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 17% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Ankündigung • May 15
Iofina plc, Annual General Meeting, Jun 09, 2025 Iofina plc, Annual General Meeting, Jun 09, 2025. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdom Reported Earnings • May 13
Full year 2024 earnings released: EPS: US$0.015 (vs US$0.034 in FY 2023) Full year 2024 results: EPS: US$0.015 (down from US$0.034 in FY 2023). Revenue: US$54.5m (up 8.9% from FY 2023). Net income: US$2.92m (down 56% from FY 2023). Profit margin: 5.4% (down from 13% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 4.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Ankündigung • Apr 19
Iofina plc Revises Production Guidance for First Half of 2025 Iofina plc revised production guidance for first half of 2025. For the period, the company now expects total iodine production for first half of 2025 to be closer to 300MT compared to the previously guided range of 320MT-355MT. The company will provide a further update on Iofina Resources' production as part of its year-end 2024 financial reporting. New Risk • Apr 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Profit margins are more than 30% lower than last year (7.0% net profit margin). Market cap is less than US$100m (UK£39.3m market cap, or US$50.2m). Price Target Changed • Dec 05
Price target increased by 7.1% to UK£0.38 Up from UK£0.35, the current price target is provided by 1 analyst. New target price is 97% above last closing price of UK£0.19. Stock is down 20% over the past year. The company posted earnings per share of US$0.034 last year. Reported Earnings • Sep 26
First half 2024 earnings released: EPS: US$0.003 (vs US$0.019 in 1H 2023) First half 2024 results: EPS: US$0.003 (down from US$0.019 in 1H 2023). Revenue: US$26.0m (up 6.9% from 1H 2023). Net income: US$607.0k (down 83% from 1H 2023). Profit margin: 2.3% (down from 15% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Ankündigung • Jul 16
Iofina plc Provides Production Guidance for the Second Half of 2024 Iofina plc provided production guidance for the second half of 2024. The company anticipates production in the second half of 2024 to be in the range of 355 MT - 380 MT. Ankündigung • May 17
Iofina plc, Annual General Meeting, Jun 13, 2024 Iofina plc, Annual General Meeting, Jun 13, 2024. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdom Ankündigung • May 16
Iofina plc Announces Resignation of William ("Bill") D. Bellamy as Director Iofina plc announced that Dr. William ("Bill") D. Bellamy, Chair of the Remuneration Committee, will retire as a Director of the Company at the close of the AGM and is therefore not being submitted for re-appointment in the business of the meeting. Reported Earnings • May 03
Full year 2023 earnings released: EPS: US$0.034 (vs US$0.041 in FY 2022) Full year 2023 results: EPS: US$0.034 (down from US$0.041 in FY 2022). Revenue: US$50.0m (up 19% from FY 2022). Net income: US$6.56m (down 17% from FY 2022). Profit margin: 13% (down from 19% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 17
Price target decreased by 13% to UK£0.35 Down from UK£0.40, the current price target is provided by 1 analyst. New target price is 67% above last closing price of UK£0.21. Stock is down 28% over the past year. The company posted earnings per share of US$0.041 last year. New Risk • Mar 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (UK£42.2m market cap, or US$53.2m). Ankündigung • Jan 15
Iofina plc Provides Market Update Regarding Its Activities During Fourth Quarter 2023 and Outlines Expectations for 2024 Iofina plc provided a market update regarding its activities during Fourth Quarter 2023 and outlines expectations for 2024. With IO#9 plant operating at an improved production rate in the second half of Fourth Quarter 2023,crystalline iodine production across Iofina Resources' six plants for the last quarter increased year over year by 16% to 160.9 metric tonnes (MT). Total production during the second half was 317.8MT, which aligned with the Company's guidance that H2 2023 production would either be at the bottom or very marginally below the forecast range of 325-350MT. This nevertheless represents a13% increase over production of 282.0MT for H2 2022. Total crystalline iodine production in 2023 was up 8% to 559.3MT, compared to 2022 production levels of 516MT. The iodine spot price softened by circa five percent over H2 2023 towards mid-to-upper sixties dollars per kilogram as prices have settled from historically high levels. Moving into 2024, the market fundamentals of the iodine business remain strong and Iofina currently expects the spot price to remain at present levels for the foreseeable future. Demand for the Company's crystalline iodine remained robust during the final quarter, whilst sales of iodine derivatives had mixed results. Regarding non-iodine products, sales of a key product mainly used in the semiconductor industry improved significantly in the second half of the year after a slower-than-anticipated first half. Moving into 2024, Iofina Resources expects to produce 275MT - 295MT of crystalline iodine during the first half (H1 2023: 242MT), which would result in a 13% to 22% increase over H1 2023. The Company reiterates that H1 iodine plant production has historically always been lower than H2 production due to the effect of lower temperatures on production in the winter months, whereas H2 production benefits from greater output in the warmer summer period. Encouraging progress has also been made regarding construction plans for IO#10 plant, with groundwork at the site scheduled to commence this week. The Company expects IO#10 iodine production to commence in Third Quarter 2024 and will update on progress as appropriate. Negotiations continue to progress well with both current and potential new brine supply partners for IO#11, and the Company continues to explore options in its current core area and other new areas for next iodine production facilities. In terms of new products, Iofina Chemical will beadding to its iodine derivatives product range in H1 2024, including an existing product in the market for which there is strong demand. The Company also expects to increase sales of its crystalline iodine to customers in Europe in 2024 through existing and new relationships. The Group is committed to operating its facilities with a safety-first approach and is proud to report that Iofina has had no lost time incidents since April 2021. Ankündigung • Oct 20
Iofina plc Provides Production Guidance for the Second Half of 2023 Iofina plc provided production guidance for the second half of 2023. the company expected second half production is trending towards the lower end of company's forecast of 325-350 MT. Reported Earnings • Sep 15
First half 2023 earnings released: EPS: US$0.019 (vs US$0.01 in 1H 2022) First half 2023 results: EPS: US$0.019 (up from US$0.01 in 1H 2022). Revenue: US$24.3m (up 27% from 1H 2022). Net income: US$3.56m (up 85% from 1H 2022). Profit margin: 15% (up from 10.0% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.7% p.a. on average during the next 2 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth. Ankündigung • Sep 12
Iofina plc Provides Production Guidance for the Second Half of 2023 Iofina plc provided production guidance for the second half of 2023. With the addition of IO#9 output, second half 2023 production is on track to meet the 325-350MT target. Price Target Changed • Aug 17
Price target increased by 13% to UK£0.40 Up from UK£0.35, the current price target is provided by 1 analyst. New target price is 33% above last closing price of UK£0.30. Stock is up 25% over the past year. The company posted earnings per share of US$0.041 last year. Ankündigung • May 09
Iofina plc, Annual General Meeting, Jun 14, 2023 Iofina plc, Annual General Meeting, Jun 14, 2023, at 09:00 Coordinated Universal Time. Location: Canaccord Genuity, 88 Wood Street London United Kingdom Agenda: To receive and adopt the reports of the directors and the auditors and the audited financial statements of the Company for the year ended 31 December 2022; to re-appoint Malcolm Lewin as director; to re-appoint Mary Fallin Christensen as a director; to re-appoint UHY Hacker Young LLP as the Company's auditors to hold office from the conclusion of the AGM to the conclusion of the next meeting at which the accounts are laid before the Company and to authorise the directors to determine remuneration. Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Mary Christensen was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 26
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: EPS: US$0.041 (down from US$0.048 in FY 2021). Revenue: US$42.2m (up 8.1% from FY 2021). Net income: US$7.87m (down 14% from FY 2021). Profit margin: 19% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.9%. Earnings per share (EPS) exceeded analyst estimates by 39%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 12
Price target increased by 7.4% to UK£0.36 Up from UK£0.34, the current price target is an average from 2 analysts. New target price is 28% above last closing price of UK£0.28. Stock is up 46% over the past year. The company is forecast to post earnings per share of US$0.024 for next year compared to US$0.048 last year. Price Target Changed • Nov 16
Price target increased to UK£0.33 Up from UK£0.30, the current price target is provided by 1 analyst. New target price is 63% above last closing price of UK£0.20. Stock is up 45% over the past year. The company is forecast to post earnings per share of US$0.025 for next year compared to US$0.048 last year. Major Estimate Revision • Oct 03
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$36.5m to US$41.5m. EPS estimate fell from US$0.03 to US$0.02. Net income forecast to shrink 29% next year vs 20% growth forecast for Chemicals industry in the United Kingdom . Consensus price target up from UK£0.30 to UK£0.33. Share price rose 5.6% to UK£0.23 over the past week. Reported Earnings • Sep 26
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: US$0.048 (up from US$0.007 in FY 2020). Revenue: US$39.0m (up 32% from FY 2020). Net income: US$9.19m (up US$7.91m from FY 2020). Profit margin: 24% (up from 4.3% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 83%. Revenue is forecast to grow 8.3% p.a. on average during the next 2 years, compared to a 7.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Price Target Changed • Sep 26
Price target increased to UK£0.33 Up from UK£0.29, the current price target is provided by 1 analyst. New target price is 48% above last closing price of UK£0.22. Stock is up 46% over the past year. The company is forecast to post earnings per share of US$0.032 for next year compared to US$0.048 last year. Major Estimate Revision • May 16
Consensus revenue estimates increase by 11% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$36.5m to US$40.3m. EPS estimate increased from US$0.03 to US$0.03 per share. Net income forecast to shrink 33% next year vs 41% growth forecast for Chemicals industry in the United Kingdom . Consensus price target up from UK£0.29 to UK£0.30. Share price rose 5.3% to UK£0.21 over the past week. Reported Earnings • May 10
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: US$0.048 (up from US$0.007 in FY 2020). Revenue: US$39.0m (up 32% from FY 2020). Net income: US$9.19m (up US$7.91m from FY 2020). Profit margin: 24% (up from 4.3% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 83%. Over the next year, revenue is forecast to grow 3.3% compared to a 18% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target increased to UK£0.29 Up from UK£0.25, the current price target is provided by 1 analyst. New target price is 33% above last closing price of UK£0.22. Stock is up 89% over the past year. The company is forecast to post earnings per share of US$0.029 for next year compared to US$0.0067 last year. Buying Opportunity • Feb 15
Now 21% undervalued Over the last 90 days, the stock is up 6.3%. The fair value is estimated to be US$0.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% per annum over the last 3 years. The company has become profitable over the last 3 years. Buying Opportunity • Jan 24
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 2.5%. The fair value is estimated to be US$0.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% per annum over the last 3 years. The company has become profitable over the last 3 years. Reported Earnings • Sep 26
First half 2021 earnings released: EPS US$0.018 (vs US$0.007 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$19.9m (up 27% from 1H 2020). Net income: US$3.50m (up 164% from 1H 2020). Profit margin: 18% (up from 8.4% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 134% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 27
Full year 2020 earnings released: EPS US$0.007 (vs US$0.003 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$29.7m (up 1.5% from FY 2019). Net income: US$1.28m (up 131% from FY 2019). Profit margin: 4.3% (up from 1.9% in FY 2019). Over the last 3 years on average, earnings per share has increased by 126% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Major Estimate Revision • Oct 17
Analysts lower EPS estimates to US$0.013 The 2020 consensus revenue estimate was lowered from US$33.1m to US$31.9m. Earning per share (EPS) estimate was also lowered from US$0.028 to US$0.013 for the same period. Net income is expected to grow by 106% next year compared to 16% growth forecast for the Chemicals industry in the United Kingdom. The consensus price target was lowered from UK£0.33 to UK£0.29. Share price is down by 1.9% to UK£0.13 over the past week. Price Target Changed • Oct 16
Price target lowered to UK£0.29 Down from UK£0.32, the current price target is provided by 1 analyst. The new target price is 119% above the current share price of UK£0.13. As of last close, the stock is down 44% over the past year. 
